Thorsten Fuereder

Pembrolizumab alone or with chemotherapy versus cetuximab with chemotherapy for recurrent or metastatic squamous cell carcinoma of the head and neck (KEYNOTE-048): a randomised, open-label, phase 3 study

Barbara Burtness, Kevin J. Harrington, Richard Greil et al. · The Lancet · 2019 · 3.2K citations · Full text

Medicine, Oncology, Cancer Pharmacology +11

Pembrolizumab With or Without Chemotherapy in Recurrent or Metastatic Head and Neck Squamous Cell Carcinoma: Updated Results of the Phase III KEYNOTE-048 Study

Kevin J. Harrington, Barbara Burtness, Richard Greil et al. · Journal of Clinical Oncology · 2022 · 490 citations · Full text

Medicine, Oncology, Pharmacotherapy +17

Trastuzumab deruxtecan in HER2-positive breast cancer with brain metastases: a single-arm, phase 2 trial

Rupert Bartsch, Anna S. Berghoff, Julia Furtner et al. · Nature Medicine · 2022 · 392 citations · Full text

Medicine, Oncology, Pharmacology +17

Neoadjuvant and Adjuvant Pembrolizumab in Locally Advanced Head and Neck Cancer

Ravindra Uppaluri, Robert I. Haddad, Yungan Tao et al. · New England Journal of Medicine · 2025 · 266 citations · Full text

Medicine, Oncology, Pharmacotherapy +17

Incidence, risk factors, and outcomes of venous and arterial thromboembolism in immune checkpoint inhibitor therapy

Florian Moik, Wei-Shin Evelyn Chan, Sarah Wiedemann et al. · Blood · 2020 · 226 citations · Full text

Medicine, Immunology, Oncology +16